Modified toxicity probability interval design: A safer and more reliable method than the 3 + 3 design for practical phase I trials

Journal of Clinical Oncology

Volumn 31, Issue 14, 2013, Pages 1785-1791

  Ji, Yuan ^a   Wang, Sue Jane ^b  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPUTER SIMULATION; CONTROLLED STUDY; EVALUATION STUDY; HUMAN; INSTITUTIONAL REVIEW; MAXIMUM TOLERATED DOSE; MODIFIED TOXICITY PROBABILITY INTERVAL DESIGN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIMULATION; SOFTWARE; TOXIC DOSE; BAYES THEOREM; BIOSTATISTICS; COMPUTER PROGRAM; DOSE RESPONSE; DRUG TOXICITY; METHODOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PROBABILITY; SAMPLE SIZE; STATISTICAL MODEL;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; BAYES THEOREM; BIOSTATISTICS; CLINICAL TRIALS, PHASE I AS TOPIC; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; HUMANS; MAXIMUM TOLERATED DOSE; MODELS, STATISTICAL; PROBABILITY; RESEARCH DESIGN; SAMPLE SIZE; SOFTWARE;

MLCS; MLOWN;

EID: 84879470827     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.7903     Document Type: Article

References (21)

1. Storer BE: An evaluation of phase I clinical trials designs in the continuous dose-response setting. Stat Med 20:2399-2408, 2001
2. Storer BE: Design and analysis of phase I clinical trials. Biometrics 45:925-937, 1989
3. Rogatko A, Schoeneck D, Jonas W, et al: Translation of innovative designs into phase I trials. J Clin Oncol 25:4982-4986, 2007
4. Le Tourneau C, Lee JJ, Siu LL: Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 101:708-720, 2009
5. Ji Y, Li Y, Nebiyou Bekele B: Dose-finding in phase I clinical trials based on toxicity probability intervals. Clin Trials 4:235-244, 2007
6. O’Quigley J, Pepe M, Fisher L: Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 46:33-48, 1990
7. Berry SM, Carlin BP, Lee JJ, et al: Bayesian Adaptive Methods for Clinical Trials. Boca Raton, FL, CRC Press, 2011
8. Cheung YK: Dose Finding by the Continual Reassessment Method. Boca Raton, FL, CRC Press, 2011
9. Neuenschwander B, Branson M, Gsponer T: Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med 27:2420-2439, 2008
10. Ji Y, Liu P, Li Y, et al: A modified toxicity probability interval method for dose-finding trials. Clin Trials 7:653-663, 2010
11. Blanchard MS, Longmate JA: Toxicity equivalence range design (TEQR): A practical phase I design. Contemp Clin Trials 32:114-121, 2011
12. Hather GJ, Mackey H: Some notable properties of the standard oncology phase I design. J Biopharm Stat 19:543-555, 2009
13. Fanale M, Fayad L, Pro B, et al: Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol 154:284-286, 2011
14. Yap TA, Yan L, Patnaik A, et al: First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29:4688-4695, 2011
15. Ibrahim NK, Desai N, Legha S, et al: Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stablized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038-1044, 2002
16. Strumberg D, Richly H, Hilger RA, et al: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractor solid tumors. J Clin Oncol 23:965-972, 2005
17. Lin Y, Shih WJ: Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. Biostatistics 2:203-215, 2001
18. Xie F, Ji Y, Tremmel L: A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials. Contemp Clin Trials 33: 739-748, 2012
19. O’Quigley J: Another look at two phase I clinical trial designs. Stat Med 18:2683-2690, 1999
20. Korn EL, Midthune D, Chen TT, et al: A comparison of two phase I designs. Stat Med 13: 1799-1806, 1994
21. Goodman SN, Zahurak ML, Piantadosi S: Some practical improvements in the continual reassessment method for phase I studies. Stat Med 14:1149-1161, 1995